ClinicalTrials.gg
Not yet recruitingNCT06103552Updated Nov 22, 2023

BLOOM Forward: Investigating Weight Loss Impact on TJAC Patients

An interventional study of Building Lifestyle Options for Orthopedic Mobility (BLOOM) in Obesity, Knee Osteoarthritis and Hip Osteoarthritis, sponsored by Ottawa Hospital Research Institute. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to prospectively assess the efficacy of the BLOOM program, a comprehensive weight loss dietary and lifestyle program, in a population of patients living with obesity and awaiting hip or knee surgery. The main questions it seeks to answer are:

  1. Can the BLOOM program support these patients to lose up to 10% of their initial body weight?
  2. Will patients continue to lose weight for the next six months after completing the program?
  3. Does the BLOOM program help patients to improve their overall quality of life?

Study participants will undergo the BLOOM program, a virtual pre-operative weight management program that spans 24 weeks and is carefully supervised by medical professionals. They will be recruited at the LEAF Clinic after being referred by their primary care physician.

During the BLOOM program, they will meet with a physician (initially, then once monthly) and a dietitian (initially, and then biweekly as part of virtual group coaching). They will have access to LEAF's online learning portal. These are normal elements of the BLOOM program.

Furthermore, as part of their participation in the research study, participants will be asked to complete the following questionnaires: the Mediterranean dietary score, the Oxford Hip and Knee Questionnaire and the EQ-D5-5L quality of life assessment. They will complete these initially, and then at completion of the program and 3 and 6 months post-program. We will also collect their height and weight at these intervals.

02

Conditions studied

  • Obesity
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Arthroplasty Complications

Keywords

  • Obesity
  • Body Mass Index
  • Weight Loss
  • Noncommunicable Diseases
  • Surveys and Questionnaires
  • Metabolic Disease
  • Arthroplasty
  • Osteoarthritis
  • Joint Diseases
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 58 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be eligible for the study, subjects must meet all the following criteria:

    1. Age ≥ 18 years old
    2. (BMI) ≥ 35 kg/m2
    3. Have being identified as a potential orthopedic surgery candidate by the Total Joint Assessment Clinic (TJAC)
    4. Have a referral by their primary care practitioner
    5. Ready to participate actively in the program (i.e., readiness to change scale score ≥7)
    6. Acquisition of the required technology tools and skills to use the virtual platform (the BLOOM program will be conducted via virtual video conference)
    7. English comprehension at a level that allows for active participation in the program

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria are not eligible for the study:

    1. Active eating disorder
    2. Active substance use disorder
    3. Active smoking
    4. Currently or past enrollment in another weight loss program in the previous year prior to enrollment in the study
    5. Ongoing pregnancy or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Weight Loss Program Intervention

    All study participants will be assigned to the intervention arm of this trial where they will undergo the BLOOM lifestyle program for weight loss. This program is 24 weeks in duration and includes group nutrition coaching with a dietitian, regular physician appointments and access to online support materials. Participants may also choose to pursue weight loss medication or meal replacement therapy, although this is not specifically part of the BLOOM program being studied.

    Behavioral: Building Lifestyle Options for Orthopedic Mobility (BLOOM)

Interventions

  • BehavioralBuilding Lifestyle Options for Orthopedic Mobility (BLOOM)

    This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.

06

What researchers measure

Primary outcomes

  1. Weight loss

    The difference (in lbs and %) in weight between the admission visit and the end of the BLOOM program

    Time frame: Weight will be compared from beginning of program to end of program, six months after program completion, and also monthly for months 1-5.

Secondary outcomes

  1. Weight - BMI 35-40

    The difference (in lbs and %) in weight between the admission visit and the end of the BLOOM program for individuals with a BMI of 35-39.9

    Time frame: Six months

  2. Weight - BMI 40+

    The difference (in lbs and %) in weight between the admission visit and the end of the BLOOM program for individuals with a BMI over 40

    Time frame: Six months

  3. Mediterranean Diet Score

    The change in the Mediterranean Dietary Score between the initial visit and the end of the BLOOM program and 3 and 6 months after

    Time frame: At program start, at program completion (approx 6 months, 3 and 6 months post-program completion (total time: twelve months)

  4. Oxford Knee and Hip

    The change in the Oxford Hip and Knee Questionnaires between the initial visit and the end of the BLOOM program and three and six months after.

    Time frame: At program start, at program completion (approx 6 months, 3 and 6 months post-program completion (total time: twelve months)

  5. EQ-5D-5L

    The change in the EQ-5D-5L quality of life (QoL) score between the initial visit and the end of the BLOOM program and three and six months after.

    Time frame: At program start, at program completion (approx 6 months, 3 and 6 months post-program completion (total time: twelve months)

  6. Decision change

    The proportion of patients that have a change of decision for joint arthropathy.

    Time frame: Twelve months

  7. Weight change

    The proportion of patients who continued to lose weight or maintained their weight 3 and 6 months after the end of the program

    Time frame: Twelve months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There is currently no plan to share IPD with other researchers, nor are we seeking institutional ethical approval for such sharing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Dec 2024, 12 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartEst.
Dec 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06103552
Collaborators
LEAF Weight Loss Clinic, The Ottawa Hospital
Responsible party
Judy Shiau (Investigator, Ottawa Hospital Research Institute) — Principal investigator
First posted
Oct 27, 2023
Start date
Dec 2023 (estimated)
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 22, 2023

Study contacts

Lesley Ananny, BA
Contact
lananny@ohri.ca
613-701-1222
Ran Cheng, MD
Contact
racheng@toh.ca
63-701-1222
Judy Shiau, MD
principal investigator · The Ottawa Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion